<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic therapy for advanced cholangiocarcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic therapy for advanced cholangiocarcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic therapy for advanced cholangiocarcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith E Stuart, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cholangiocarcinomas are rare malignancies arising from the epithelial cells of the intrahepatic and extrahepatic bile ducts. Cholangiocarcinoma is an aggressive tumor that can metastasize beyond the bile ducts to other intrahepatic locations, the peritoneum, and distant extrahepatic organs. (See  <a class="medical medical_review" href="/z/d/html/2500.html" rel="external">"Clinical manifestations and diagnosis of cholangiocarcinoma"</a>.)</p><p>The approach to systemic therapy for advanced and metastatic cholangiocarcinoma will be reviewed here. Adjuvant and neoadjuvant therapy for localized cholangiocarcinoma, treatment of locally advanced unresectable nonmetastatic cholangiocarcinoma, systemic therapy for ampullary cancer, and systemic therapy for gallbladder cancer are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2467.html" rel="external">"Adjuvant and neoadjuvant therapy for localized cholangiocarcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2497.html" rel="external">"Treatment options for locally advanced, unresectable, but nonmetastatic cholangiocarcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2506.html" rel="external">"Ampullary carcinoma: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2499.html" rel="external">"Treatment of advanced, unresectable gallbladder cancer"</a>.)</p><p></p><p class="headingAnchor" id="H269655511"><span class="h1">INITIAL THERAPY</span><span class="headingEndMark"> — </span>The approach to initial systemic therapy for advanced biliary tract cancer is evolving. Chemotherapy is an integral part of initial therapy [<a href="#rid1">1</a>], but no chemotherapy regimen alone consistently extends survival beyond 8 to 15 months. Therefore, we encourage enrollment in clinical trials, where available. Of note, many clinical trials often enroll patients with different histologies such as cholangiocarcinoma, gallbladder cancer, and ampullary cancer. Although they arise in similar locations, these cancers all have a unique natural history and response to therapy [<a href="#rid2">2</a>]. For patients who are ineligible for or decline clinical trials, our approach to initial therapy is based on patient performance status and bilirubin levels.</p><p class="headingAnchor" id="H1638837121"><span class="h2">Good performance status and no hyperbilirubinemia</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic cholangiocarcinoma who have good ECOG performance status (less than 2)  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a>) and a no hyperbilirubinemia (total bilirubin less than 2.5 times the upper limit of normal [ULN]), we suggest the addition of immunotherapy (either <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> or <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>) to <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> as initial treatment, as these regimens improved overall survival (OS) and demonstrated durable responses in separate randomized trials [<a href="#rid3">3,4</a>]. Although either chemoimmunotherapy regimen is appropriate, gemcitabine plus cisplatin and durvalumab has the advantage of a simpler maintenance regimen with single-agent durvalumab every four weeks, which may be preferred by some patients and providers. (See <a class="local">'Gemcitabine plus cisplatin and durvalumab'</a> below and <a class="local">'Gemcitabine plus cisplatin and pembrolizumab'</a> below.)</p><p>For patients who decline chemoimmunotherapy or are anticipated to not tolerate its toxicities, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef89633" href="/z/d/graphic/89633.html" rel="external">table 2</a>) is an appropriate alternative, given combination chemoimmunotherapy confers a modest OS benefit. (See <a class="local">'Gemcitabine plus cisplatin'</a> below.)</p><p>Other options for initial therapy include <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, gemcitabine plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, gemcitabine plus <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a>, and gemcitabine plus S-1 (where available). (See <a class="local">'Other regimens'</a> below.)</p><p class="headingAnchor" id="H4259226201"><span class="h3">Gemcitabine plus cisplatin and durvalumab</span><span class="headingEndMark"> — </span>The addition of <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> to <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> improves OS and has durable responses in patients with treatment-naïve advanced or metastatic biliary tract tumors and no hyperbilirubinemia (ie, total bilirubin less than 2.5 times the ULN). After completion of induction chemoimmunotherapy, maintenance therapy consists of single-agent durvalumab every four weeks until disease progression or unacceptable toxicity. </p><p><a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> was investigated in a double-blind, placebo-controlled phase III trial (TOPAZ-1) of 685 patients with previously untreated, unresectable locally advanced or metastatic biliary tract cancer. Patients had either intrahepatic cholangiocarcinoma (56 percent), extrahepatic cholangiocarcinoma (19 percent), or gallbladder cancer (25 percent) [<a href="#rid3">3</a>]. In this study, patients were randomly assigned to receive either durvalumab (1500 mg every three weeks) or placebo in combination with gemcitabine (1000 mg/m<sup>2</sup>) and cisplatin (25 mg/m<sup>2</sup>) on days 1 and 8 every three weeks for up to eight cycles. Patients subsequently received maintenance therapy with either durvalumab (1500 mg every four weeks) or placebo until disease progression or unacceptable toxicity.</p><p>At median follow-up of 17 months, compared with placebo plus chemotherapy, <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> plus chemotherapy improved OS (median 12.8 versus 11.5 months, HR 0.8, 95% CI 0.66-0.97), progression-free survival (median 7.2 versus 5.7 months, two-year OS 25 versus 10 percent, hazard ratio [HR] 0.75, 95% CI 0.63-0.89), and objective response rate (27 versus 19 percent). OS benefits were generally seen across clinically relevant subgroups including those with intrahepatic cholangiocarcinoma (HR 0.76, 95% CI 0.58-0.98), extrahepatic cholangiocarcinoma (HR 0.76), gallbladder cancer (HR 0.94), and PD-L1 expression: total area positivity ≥1 (HR 0.79, 95% CI 0.61-1.00). The proportion of ongoing responses lasting one year or longer for durvalumab versus placebo were 26 and 15 percent, respectively.</p><p>Combining <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> with chemotherapy also did not increase toxicity compared to placebo with chemotherapy (grade 3 to 4 toxicity rates of 76 versus 78 percent). (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p>Based on these data, the US Food and Drug Administration (FDA) has approved <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>, in combination with <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, for adult patients with locally advanced or metastatic biliary tract cancers [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3275727965"><span class="h3">Gemcitabine plus cisplatin and pembrolizumab</span><span class="headingEndMark"> — </span>The addition of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> to <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> is an option for initial therapy in patients with advanced or metastatic biliary tract tumors. In a phase III trial, this combination improved OS with durable responses and was well-tolerated [<a href="#rid4">4</a>]. After completion of induction chemoimmunotherapy, maintenance therapy for most patients consisted of both gemcitabine and pembrolizumab for up to 35 cycles (two years), including induction cycles, followed by gemcitabine monotherapy until disease progression or unacceptable toxicity.</p><p><a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> was evaluated in a double-blind placebo-controlled phase III trial (KEYNOTE-966) of 1069 patients with previously untreated locally advanced or metastatic biliary tract cancer, including intrahepatic (59 percent) or extrahepatic cholangiocarcinoma (19 percent) and gallbladder cancer (22 percent) [<a href="#rid4">4</a>]. In this study, patients were randomly assigned to either pembrolizumab (200 mg every three weeks) or placebo, in combination with gemcitabine (1000 mg/m<sup>2</sup><sub> </sub>on days 1 and 8 every three weeks) plus cisplatin (25 mg/m<sup>2</sup> on days 1 and 8 every three weeks) for up to eight cycles. For maintenance therapy, gemcitabine could be continued with no maximum duration and pembrolizumab or placebo was continued for up to 35 cumulative cycles (two years), or until disease progression or unacceptable toxicity. Patients who discontinued gemcitabine, cisplatin, or both due to toxicity could continue pembrolizumab or placebo, and vice-versa.</p><p>At median follow-up of 26 months, compared with placebo plus chemotherapy, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus chemotherapy improved OS (median OS 12.7 versus 10.9 months, two-year OS 25 versus 18 percent, HR 0.83, 95% CI 0.72-0.95). Progression-free survival (median 6.5 versus 5.6 months, HR 0.86, 95% CI 0.75-1.00) and objective response rates (29 percent each) were similar between the treatment arms. OS benefits were generally seen across all clinically relevant subgroups, including those with intrahepatic cholangiocarcinoma (HR 0.76, 95% CI 0.64-0.91), extrahepatic cholangiocarcinoma (HR 0.99), and gallbladder cancer (HR 0.96), and PD-L1 combined positive score (CPS) ≥1 (HR 0.85, 95% CI 0.72-1.00). The proportion of ongoing responses at two years or longer for pembrolizumab versus placebo were 18 and 6 percent, respectively.</p><p>Combining <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> with chemotherapy also did not significantly increase toxicity compared with placebo plus chemotherapy (grade 3 to 4 toxicity of 79 versus 75 percent). (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p><a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is approved by the US FDA for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC) [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H269656209"><span class="h3">Gemcitabine plus cisplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef89633" href="/z/d/graphic/89633.html" rel="external">table 2</a>) is an appropriate alternative for patients with treatment-naïve advanced cholangiocarcinoma, good ECOG performance status, and no hyperbilirubinemia (ie, total bilirubin less than 2.5 times the ULN) who decline chemoimmunotherapy or are anticipated to not tolerate its toxicities. Gemcitabine plus cisplatin improved OS over single-agent gemcitabine in a randomized trial [<a href="#rid7">7</a>], but it has not been directly compared with other gemcitabine-based combinations, except for gemcitabine plus S-1. (See <a class="local">'Gemcitabine plus S-1'</a> below.) Gemcitabine plus cisplatin is also well tolerated in most studies [<a href="#rid8">8-13</a>].</p><p>In initial clinical trials of advanced biliary tract cancers, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> demonstrated higher objective response rates and tumor control compared with regimens that did not include gemcitabine or <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid13">13</a>]. These data led to the conduct of an open-label phase III trial (ABC-02) of 410 patients with locally advanced or metastatic bile duct (59 percent), gallbladder (36 percent), or ampullary (5 percent) cancer [<a href="#rid7">7</a>]. In this study, patients were randomly assigned to 24 weeks of either gemcitabine (1000 mg/m<sup>2</sup>) plus cisplatin (25 mg/m<sup>2</sup>) on days 1 and 8 every 21 days, or gemcitabine alone (1000 mg/m<sup>2</sup> on days 1, 8, and 15 every 28 days).</p><p>At a median follow-up of approximately eight months, the combination improved OS (median 11.7 versus 8.1 months, HR 0.64, 95% CI 0.52-0.80) and PFS (median 8 versus 5 months, HR 0.63, 95% CI 0.51-0.77) compared with <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> alone. Toxicity was similar in both treatment arms, except for higher rates of grade 3 or 4 neutropenia with gemcitabine plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (25 versus 17 percent) and grade 3 or 4 abnormal liver function with gemcitabine alone (27 versus 17 percent). Most quality of life scales showed a trend favoring combined therapy, although the differences were not statistically significant [<a href="#rid14">14</a>]. Of the 21 long-term (&gt;3 years) survivors, two-thirds (14 survivors) had received gemcitabine plus cisplatin.</p><p>Similar results were also seen in a separate randomized trial conducted in Japan, which also demonstrated an overall survival benefit for the combination over single-agent <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> (11.2 versus 7.7 months) [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3404237595"><span class="h3">Other regimens</span><span class="headingEndMark"> — </span>Other regimens are also available for initial treatment of advanced cholangiocarcinoma.</p><p class="headingAnchor" id="H2900538797"><span class="h4">Gemcitabine plus oxaliplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (GEMOX) is an alternative option for initial therapy in advanced cholangiocarcinoma. GEMOX is used by some institutions since it is an active, well-tolerated regimen that was non-inferior to CAPOX in a phase III trial [<a href="#rid15">15</a>]. However, GEMOX has not been directly compared with gemcitabine plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> in randomized trials. In addition, initial therapy with GEMOX precludes the option of second-line therapy with <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> and oxaliplatin (FOLFOX) due to prior oxaliplatin exposure. (See <a class="local">'Patients initially treated with gemcitabine plus oxaliplatin'</a> below.)</p><p>Based on initial data from observational studies and early phase clinical trials [<a href="#rid16">16-20</a>], a randomized open-label phase III, noninferiority trial was conducted comparing GEMOX to <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (CAPOX) in 222 patients with treatment-naive advanced biliary tract cancer. In this study, GEMOX was non-inferior to CAPOX for OS (median 10.4 versus 10.6 months) and PFS (six-month PFS 45 versus 47 percent) [<a href="#rid15">15</a>]. Objective response rates were higher for GEMOX compared with CAPOX, but the difference was not statistically significant (25 versus 16 percent). Grade ≥3 toxicity rates were similar between the two treatment arms. Common grade 3 to 4 toxicities for GEMOX included neutropenia (14 percent) and thrombocytopenia (11 percent), and there were two cases of febrile neutropenia (1 percent).</p><p>The addition of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> to GEMOX has been investigated in clinical trials [<a href="#rid21">21</a>], but this approach remains investigational.</p><p class="headingAnchor" id="H269656437"><span class="h4">Gemcitabine plus capecitabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> is an active, well-tolerated regimen in advanced biliary tumors, based on data from phase II trials [<a href="#rid22">22-27</a>]. Although gemcitabine plus capecitabine is a reasonable alternative for initial therapy, it has not been directly compared with gemcitabine plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> in randomized trials.</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-arm phase II trial, 45 patients with advanced cholangiocarcinoma or gallbladder cancer were treated with <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> (1000 mg/m<sup>2</sup> on days 1 and 8) plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> (650 mg/m<sup>2</sup> twice daily for 14 days of every 21-day cycle) [<a href="#rid22">22</a>]. The objective response rate was 31 percent, including two complete responses (one for each tumor type). Median PFS and OS were 7 and 14 months, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate phase II trial conducted by the Southwest Oncology Group (SWOG) of 57 patients with advanced biliary tract cancer, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> demonstrated an objective response rate of 25 percent, but median OS was 7 months [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H2755930948"><span class="h4">Gemcitabine plus nabpaclitaxel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> plus nanoparticle albumin-bound <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> (<a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a>  (<a class="graphic graphic_table graphicRef89668" href="/z/d/graphic/89668.html" rel="external">table 3</a>)) is also an active initial regimen in advanced biliary tumors. This regimen is an appropriate alternative for those with a contraindication to, or without access to  (<a class="graphic graphic_table graphicRef141828" href="/z/d/graphic/141828.html" rel="external">table 4</a>), <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. However, this combination has not been directly compared with gemcitabine plus cisplatin in randomized trials. In a single-arm phase II trial of 74 patients with advanced or metastatic cholangiocarcinoma, gemcitabine plus nabpaclitaxel had an objective response rate was 30 percent [<a href="#rid28">28</a>]. Median PFS and OS were 8 and 12 months, respectively. Common grade ≥3 toxicities included neutropenia (43 percent) and fatigue (14 percent).</p><p>Although the triplet combination of <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a> is also active in advanced cholangiocarcinoma, we do not use this regimen due to risk of increased toxicity and availability of other better-tolerated triplet therapies (ie, chemoimmunotherapy). Gemcitabine plus cisplatin and nabpaclitaxel was investigated in a phase II study of 60 patients with locally advanced unresectable or metastatic biliary tract cancer, including gallbladder and cholangiocarcinoma [<a href="#rid29">29</a>]. At median follow-up of 12 months, the objective response rate was 45 percent. Median PFS and OS were 12 and 19 months, respectively. The grade ≥3 toxicity rate was 58 percent, and the most frequent was neutropenia (33 percent). In addition, nine patients (16 percent) withdrew from the trial because of adverse events.</p><p class="headingAnchor" id="H2672368809"><span class="h4">Gemcitabine plus S-1</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">Gemcitabine</a> plus S-1 is an option for initial treatment of advanced cholangiocarcinoma that was non-inferior to gemcitabine plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> in a randomized phase III trial [<a href="#rid30">30</a>]. S-1, which is available in some countries outside of the United States, is an oral fluoropyrimidine that includes three different agents: ftorafur (tegafur), gimeracil (5-chloro-2,4-dihydropyridine, a potent inhibitor of the FU-metabolizing enzyme dihydropyridine dehydrogenase [DPD]), and oteracil (potassium oxonate, which inhibits phosphorylation of intestinal FU, thought responsible for treatment-related diarrhea).</p><p>In a phase III non-inferiority trial (FUGA-BT) conducted in Japan, 354 patients with chemotherapy-naïve recurrent or unresectable adenocarcinoma of the gallbladder, biliary tract, or ampulla of Vater were randomly assigned to either <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> (1000 mg/m<sup>2</sup> on days 1 and 8) plus S-1 (60, 80, or 100 mg daily based on body surface area and administered on days 1 to 14 of a 21-day cycle) or gemcitabine plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef89633" href="/z/d/graphic/89633.html" rel="external">table 2</a>) [<a href="#rid30">30</a>]. Relative to gemcitabine plus cisplatin, gemcitabine plus S-1 demonstrated noninferior OS (median 15.1 versus 13.4 months, HR 0.95, 95% CI 0.78-1.15), PFS (median 6.8 versus 5.8 months, HR 0.86, 95% CI 0.70-1.07), and objective response rate (30 versus 32 percent). Both treatments were generally well tolerated, although clinically relevant adverse effects (grade 2 or worse fatigue, anorexia, nausea, vomiting, mucositis, and diarrhea) were slightly more frequent with gemcitabine plus cisplatin (35 versus 31 percent).</p><p class="headingAnchor" id="H2773041502"><span class="h4">Non-gemcitabine-based regimens</span><span class="headingEndMark"> — </span>We prefer a gemcitabine-containing regimen as initial therapy for patients with advanced cholangiocarcinoma and no hyperbilirubinemia (ie, total bilirubin less than 2.5 times the ULN). However, data from randomized trials are insufficient to conclude that gemcitabine-based combinations are superior to non-gemcitabine-based regimens.</p><p class="bulletIndent1"><span class="glyph">●</span>Various randomized trials have directly compared gemcitabine-containing with non-gemcitabine-containing chemotherapy or chemoradiotherapy for initial therapy of advanced biliary tract cancer [<a href="#rid31">31-37</a>]. A Cochrane analysis concluded that the evidence obtained from these low-quality trials was insufficient to prove whether or not gemcitabine-containing combinations are better than non-gemcitabine-containing combinations, and that additional studies were needed [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent randomized phase II trial (PRODIGE 38 AMEBICA) of 191 patients with advanced biliary tract cancer (mostly cholangiocarcinoma) modified FOLFIRINOX  (<a class="graphic graphic_table graphicRef109546" href="/z/d/graphic/109546.html" rel="external">table 5</a>) failed to improve OS or PFS relative to <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>.</p><p></p><p class="headingAnchor" id="H3320067526"><span class="h2">Good performance status and persistent biliary obstruction</span></p><p class="headingAnchor" id="H1612856969"><span class="h3">Fluorouracil-based regimens</span><span class="headingEndMark"> — </span>For patients with a good performance status who have hyperbilirubinemia despite stenting, we prefer a non-gemcitabine-based regimen, such as LV-modulated FU  (<a class="graphic graphic_table graphicRef65525" href="/z/d/graphic/65525.html" rel="external">table 6</a>) or a fluoropyrimidine plus <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> such as FOLFOX or CAPOX.</p><p>In past studies, objective response rates for FU alone or FU-based combination therapies ranged from 0 to 34 percent, and median survival was typically less than six months. Many, but not all, more recent series using either infusional FU in combination regimens or LV-modulated FU report higher response rates and marginally longer survival (but still less than one year) [<a href="#rid39">39-46</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Borderline performance status</span><span class="headingEndMark"> — </span>For patients with a borderline performance status or extensive comorbidity, options for initial therapy include LV-modulated FU  (<a class="graphic graphic_table graphicRef65525" href="/z/d/graphic/65525.html" rel="external">table 6</a>), single-agent <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, and single-agent <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>  (<a class="graphic graphic_table graphicRef60330" href="/z/d/graphic/60330.html" rel="external">table 7</a>).</p><p class="headingAnchor" id="H5"><span class="h3">Leucovorin-modulated fluorouracil</span><span class="headingEndMark"> — </span>Objective response rates with FU alone are low, and median survival is typically short (usually less than six months) [<a href="#rid41">41</a>]. Higher response rates are reported in many series using either infusional FU or LV-modulated FU, although whether this translates into better survival is unclear [<a href="#rid42">42-49</a>]. In one report of 28 patients with advanced biliary tract cancer, FU (375 mg/m<sup>2</sup> per day by bolus) plus LV (25 mg/m<sup>2</sup> per day) was given on days 1 through 5 every three to four weeks [<a href="#rid44">44</a>]. There were nine objective responses (32 percent), two of which were complete and lasted for 14 and 16 months, respectively. However, median survival for the entire group was only six months.</p><p>Regimens that combine short-term infusional FU with LV (eg, the de Gramont schedule  (<a class="graphic graphic_table graphicRef65525" href="/z/d/graphic/65525.html" rel="external">table 6</a>)) are better tolerated than bolus regimens, and these are generally preferred, although they require central venous access.</p><p class="headingAnchor" id="H3107146267"><span class="h3">Capecitabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">Capecitabine</a> monotherapy is a reasonable alternative to LV-modulated FU for initial therapy in patients with a borderline performance status, although for unclear reasons, capecitabine as a single agent appears to be relatively less active for cholangiocarcinoma than for gallbladder cancer [<a href="#rid50">50,51</a>]. (See  <a class="medical medical_review" href="/z/d/html/2499.html" rel="external">"Treatment of advanced, unresectable gallbladder cancer", section on 'Borderline performance status'</a>.)</p><p class="headingAnchor" id="H2919662498"><span class="h3">Gemcitabine alone</span><span class="headingEndMark"> — </span>Although it is better tolerated than combination therapy, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> alone has been associated with inferior outcomes when compared with gemcitabine-based doublets [<a href="#rid7">7,11,52,53</a>]. Overall, objective response rates with gemcitabine alone range from 7 to 27 percent, but median survival is rarely longer than eight months [<a href="#rid8">8,54,55</a>]. </p><p>Although randomized trials have not been carried out, the combination of FU/LV and <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> does not appear to be substantially more active than gemcitabine alone [<a href="#rid56">56-58</a>]. </p><p class="headingAnchor" id="H4159013411"><span class="h3">Biweekly gemcitabine plus cisplatin</span><span class="headingEndMark"> — </span>Another option is biweekly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, which is associated with a more favorable toxicity profile than standard cisplatin plus gemcitabine [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H269657981"><span class="h1">SECOND-LINE THERAPY AND BEYOND</span><span class="headingEndMark"> — </span>There are few prospective trials comparing specific chemotherapy regimens in the second-line setting for advanced cholangiocarcinoma, and the selection of candidates for second-line therapy as well as the optimal regimen are not established. Targeted testing of advanced cholangiocarcinomas for mismatch repair deficiency (dMMR)/microsatellite instability (MSI) and for specific molecular alterations for which a targeted treatment might be available is indicated for those who might be eligible for molecularly targeted therapy or immunotherapy, preferably within the context of a clinical trial. (See <a class="local">'Molecularly targeted therapy'</a> below.)</p><p class="headingAnchor" id="H3039236047"><span class="h2">Prognostic stratification</span><span class="headingEndMark"> — </span>The optimal selection of candidates for second-line chemotherapy is not established. Three independent studies suggest that patients who have a good performance status (0 or 1  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a>)), disease control with initial chemotherapy, a relatively low carbohydrate antigen 19-9 (CA 19-9) level, an absence of peritoneal carcinomatosis, and possibly, previous surgery on their primary tumor have the longest survival with second-line chemotherapy [<a href="#rid60">60-62</a>], but whether these characteristics predict chemotherapy responsiveness or more favorable biologic behavior is not clear. No particular regimen seems superior to any other, and the choice of second-line regimen is empiric [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H3552703949"><span class="h2">Cytotoxic chemotherapy</span><span class="headingEndMark"> — </span>Largely based on the ABC-06 trial, for most patients who have disease progression while receiving <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and who retain an adequate performance status, in the absence of potentially actionable molecular targets, we suggest treatment with short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (LV) and <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (FOLFOX). Other conventional chemotherapy regimens that could be considered in this setting include gemcitabine plus oxaliplatin (GEMOX) with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus oxaliplatin (CAPOX), <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a> plus leucovorin-modulated FU, or a fluoropyrimidine alone. (See <a class="local">'Gemcitabine plus oxaliplatin'</a> above.)</p><p>After failure of GEMOX, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, capecitabine plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, or short-term infusional FU plus LV and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> (FOLFIRI) with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> are appropriate options. For selected patients, second-line molecularly targeted therapy using <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> plus bevacizumab may be considered; however, this regimen is highly costly.</p><p class="headingAnchor" id="H521126709"><span class="h3">Patients initially treated with gemcitabine plus cisplatin</span></p><p class="headingAnchor" id="H3948953722"><span class="h4">FOLFOX</span><span class="headingEndMark"> — </span>Short-term infusional FU plus LV and <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (FOLFOX,  (<a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">table 8</a>)) is an active regimen for second-line therapy [<a href="#rid53">53,63,64</a>]. FOLFOX was directly compared with active symptom control alone in the randomized ABC-06 trial, which enrolled 162 patients with disease progression after prior <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>; there were 117 patients with cholangiocarcinoma, 34 with gallbladder cancer, and 11 with ampullary cancer [<a href="#rid65">65</a>]. FOLFOX was associated with significantly better rates of overall survival at 6 (51 versus 36 percent) and 12 months (26 versus 11 percent), and significantly, albeit modestly, improved median overall survival (6.2 versus 5.3 months, hazard ratio [HR] 0.69, 95% CI 0.50-0.97). Grade 3 or 4 toxic events were reported in 59 percent of the group receiving FOLFOX (versus 37 percent of those undergoing symptom control alone), with fatigue and neutropenia being more frequent in the FOLFOX arm. Notably, the protocol allowed for an initial 20 percent reduction in <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> dose for individuals older than 70, and a reduced initial oxaliplatin dose (65 rather than 85 mg/m<sup>2</sup>) if the creatinine clearance was 30 to 60 mL/min.</p><p class="headingAnchor" id="H1874734594"><span class="h4">Liposomal irinotecan</span><span class="headingEndMark"> — </span>A benefit for second-line <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a> in combination with <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> [LV]-modulated short-term infusional FU  (<a class="graphic graphic_table graphicRef109026" href="/z/d/graphic/109026.html" rel="external">table 9</a>) compared with FU/LV alone after progression on <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> was addressed in the phase II NIFTY trial [<a href="#rid66">66</a>]. Of the 174 patients who were assessable for response, median progression-free survival (the primary endpoint, as assessed by blinded independent central review) was significantly better in the <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> group (7.1 versus 1.4 months) as was median overall survival (8.6 versus 5.5 months) and objective response rate (15 versus 6 percent). The most common grade 3 or worse adverse events in the irinotecan group were neutropenia, fatigue, and nausea.</p><p class="headingAnchor" id="H3588094667"><span class="h4">Capecitabine plus oxaliplatin</span><span class="headingEndMark"> — </span>All of the data on CAPOX are in the initial setting:</p><p class="bulletIndent1"><span class="glyph">●</span>Benefit for CAPOX for initial therapy was also shown in a phase II trial of 65 patients with advanced biliary cancer (38 with intrahepatic or extrahepatic cholangiocarcinoma) [<a href="#rid26">26</a>]. Among the patients with extrahepatic bile duct cholangiocarcinoma, there were two complete and eight partial responses. There were no partial or complete responses among patients with intrahepatic mass-forming cholangiocarcinoma. Treatment was well tolerated, with only mild hematologic toxicity, grade 3 or 4 peripheral neuropathy in 11 patients of the entire cohort, and two hypersensitivity reactions to <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others have demonstrated noninferiority for CAPOX compared with GEMOX as initial therapy for advanced biliary tract cancer [<a href="#rid15">15</a>].</p><p></p><p>We would not pursue CAPOX for a patient initially treated with GEMOX. However, second-line therapy with this combination may be an appropriate alternative to FOLFOX after failure of <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>.</p><p class="headingAnchor" id="H4176506406"><span class="h4">Capecitabine plus irinotecan</span><span class="headingEndMark"> — </span>Another second-line alternative after failing initial <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> is XELIRI. However, in our view, given the potential for treatment-related toxicity, other regimens such as <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a> plus leucovorin-modulated FU are preferred.</p><p>XELIRI (<a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> 180 mg/m<sup>2</sup> on day 1 plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> 1000 mg/m<sup>2</sup> twice daily on days 1 to 10 of every 14-day cycle) was directly compared with irinotecan alone (180 mg/m<sup>2</sup> on day 1 of each 14-day cycle) in a randomized phase II trial of 64 patients with advanced biliary tract cancer (12 with gallbladder cancer, the remainder with cholangiocarcinoma) previously treated with <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid67">67</a>]. Median progression-free survival (3.7 versus 2.4 months) and nine-month survival (61 versus 32 percent) were significantly better with combined therapy, although the difference in median overall survival was not significant (10.1 versus 7.3 months, p = 0.107). Rates of severe (grade 3 or 4) toxicity were not much worse with combined therapy, with the exception of palmar-plantar erythrodysesthesia (6.7 versus 0 percent).</p><p class="headingAnchor" id="H1331872310"><span class="h4">Fluoropyrimidine alone</span><span class="headingEndMark"> — </span>Whether results are better with FOLFOX or CAPOX than a fluoropyrimidine alone is unclear; there are no randomized trials. One retrospective analysis of 321 patients who received a fluoropyrimidine-based second-line regimen after failing <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> concluded that the objective response rate was higher with a fluoropyrimidine-platinum combination (8 versus 1 percent) but that progression-free and overall survival were not significantly better [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H2492052810"><span class="h4">Antiangiogenic therapy</span><span class="headingEndMark"> — </span>Angiogenesis is an important target in biliary tract cancers, as vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) overexpression are reported in 30 to 50 percent of tumors and associated with a poor prognosis [<a href="#rid69">69</a>]. Unfortunately, the benefits in clinical trials have been modest, at best.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bevacizumab</strong> – The efficacy of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, a monoclonal antibody targeting VEGF, in combination with a variety of other drugs has been promising in uncontrolled studies in metastatic biliary tract cancer [<a href="#rid21">21,70-73</a>], but the contribution of this agent remains uncertain due to the lack of controlled trials. Bevacizumab plus <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> is discussed below. (See <a class="local">'What is the role of EGFR inhibitors?'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regorafenib</strong> – <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">Regorafenib</a> is an orally active inhibitor of angiogenic (including the VEGFRs 1 to 3), stromal, and oncogenic receptor tyrosine kinases that targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways.</p><p></p><p class="bulletIndent1">A benefit for <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> compared with best supportive care after failure of <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> and platinum-based chemotherapy was noted in REACHIN, a randomized double-blind phase II trial [<a href="#rid74">74</a>]. Overall, 66 patients were randomly assigned to regorafenib (160 mg daily) or an identically matched placebo. Median progression-free survival, the primary endpoint, was modestly but significantly higher with regorafenib (3.0 versus 1.5 months), and the disease control rate was also higher (70 versus 33 percent); however, median overall survival was similar (5.3 versus 5.1 months). The most common treatment-related grade 3 or 4 toxicities with regorafenib were fatigue (18 percent), nausea and vomiting (9 percent), and skin toxicity (9 percent).</p><p></p><p class="bulletIndent1">A similar modest degree of benefit was reported in another open label multi-institutional trial conducted in patients with heavily pretreated advanced biliary tract cancer (median progression-free survival 3.7 months, disease control rate 64 percent [<a href="#rid75">75</a>]).</p><p></p><p class="bulletIndent1">Given these modest benefits, we would not pursue <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> as a second-line strategy but consider it an option for third-line therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ramucirumab</strong> – <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">Ramucirumab</a> is a fully human IGG1 monoclonal antibody that targets VEGFR2, inhibiting the biding of VEGF. Activity in advanced pretreated biliary tract cancer was shown in a phase II study of 61 patients (62 percent intrahepatic cholangiocarcinoma, 17 percent extrahepatic, and the remainder gallbladder cancer); all had received <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> frontline, and eight had received four or more prior therapies [<a href="#rid76">76</a>]. One patient achieved a partial response, and the disease control rate overall was 45 percent. Median progression-free survival was 3.2 months, and median overall survival 9.5 months. Ramucirumab was well tolerated, and the majority of toxicities were grade 1 or 2.</p><p></p><p class="bulletIndent1">Whether these results are better than can be achieved with any other salvage regimen in this setting is not clear; there are no comparator trials.</p><p></p><p class="headingAnchor" id="H3113700364"><span class="h3">Patients initially treated with gemcitabine plus oxaliplatin</span></p><p class="headingAnchor" id="H1636840676"><span class="h4">Gemcitabine plus capecitabine</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> is active for advanced biliary tumors.</p><p class="headingAnchor" id="H2246842525"><span class="h4">Capecitabine plus cisplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">Capecitabine</a>, as an alternative to infusional FU, has been investigated in combination with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. A relatively large (although retrospective) study of 176 patients reported a 17 percent response rate and median survival of 7.4 months [<a href="#rid77">77</a>]. Another smaller but prospective study achieved a similar 21 percent response rate and median survival of 9.1 months [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H3019413394"><span class="h4">FOLFIRI with or without bevacizumab</span><span class="headingEndMark"> — </span>The efficacy of second-line short-term infusional FU plus LV and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> (FOLFIRI) plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> was addressed in a small retrospective analysis of 13 patients who were refractory to initial therapy with GEMOX [<a href="#rid70">70</a>]. There were five objective responders (one complete), and median overall survival was 20 months.</p><p class="headingAnchor" id="H3886584813"><span class="h2">Molecularly targeted therapy</span><span class="headingEndMark"> — </span>Targeted testing of advanced cholangiocarcinomas for dMMR/MSI and for specific molecular alterations for which a targeted treatment might be available is indicated for those who might be eligible for molecularly targeted therapy or immunotherapy, preferably within the context of a clinical trial [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H1228184521"><span class="h3">Next-generation sequencing to identify actionable molecular abnormalities</span><span class="headingEndMark"> — </span>Several ongoing trials (eg, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02465060%3Fterm%3DNCI%2BMATCH%26draw%3D1%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPxbeelusmB2xSWfifmrxxLsYWSGc8i4h9%2B%2BhXZZiCTEepYPjUUxu%2F7002cOTJi%2B8xoWjzBvMXD%2BC2CnIEVXLcV&amp;TOPIC_ID=2524" target="_blank">National Cancer Institute [NCI] Molecular Analysis for Therapy Choice [MATCH]</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02693535%3Fterm%3DTAPUR%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMEVm2FngAlvWosYKhHNJLkxP82kgf2SMoa3qVhs2WwS3bfqMOGVCfS1Hai2AzxDvQ%3D&amp;TOPIC_ID=2524" target="_blank">ASCO Targeted Agent and Profiling Utilization Registry [TAPUR]</a> trails) are using next-generation sequencing (NGS) of multiple genes (gene panel tests) to identify molecular abnormalities in the tumors of patients with refractory cancers that may potentially match molecularly targeted therapies that are either in clinical trials or approved for treatment of other cancer types. Two such gene panel tests (MSK-IMPACT [Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets] and F1CDx [FoundationOne CDx]) are US Food and Drug Administration (FDA) approved in the United States. These tests can be used on formalin-fixed, paraffin-embedded (FFPE) tissue regardless of the primary organ from which the tumor arose. (See  <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Cancer screening and management'</a>.)</p><p>Biliary tract carcinomas (particularly intrahepatic cholangiocarcinomas) have multiple molecular alterations, many of which are potential targets for available specific inhibitors [<a href="#rid80">80-87</a>]. For patients without a molecular alteration, or those with molecular alterations for which a targeted treatment is not available, clinical trial enrollment is encouraged, where available.</p><p>The potential impact of this approach in patients with advanced biliary tract cancer can be illustrated by the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Molecular Screening for Cancer Treatment Optimization (MOSCATO)-01 trial, 43 of 1035 adults with advanced cancer had a biliary tract malignancy, 34 of whom successfully underwent high-throughput molecular screening on fresh frozen tissue [<a href="#rid86">86</a>]. Potentially actionable molecular aberrations were identified in 23 patients (68 percent), 18 of whom received targeted treatment. Median progression-free survival was 5.2 months, and there were six objective responses (33 percent, one complete).</p><p></p><p class="bulletIndent1">Interestingly, all of the patients harboring a fusion transcript involving the fibroblast growth factor receptor 2 (FGFR2) and the single patient with an <em>FGFR2</em> mutation had dramatic responses with therapeutic FGFR inhibition. Others have reported favorable results from the targeting of <em>FGFR </em>mutations/fusions in advanced cholangiocarcinoma [<a href="#rid88">88-90</a>]. These data are discussed below. (See <a class="local">'FGFR inhibitors for FGFR fusion-positive tumors'</a> below.)</p><p></p><p class="bulletIndent1">The two best responders in this series had been treated with human epidermal growth factor 2 (HER2) inhibitors, one of whom had amplification of <em>ERBB2</em> and the other had a mutation in <em>ERBB3</em>.</p><p></p><p class="bulletIndent1">Besides these, other promising targets for biliary tract cancers include mutations in the isocitrate dehydrogenase (IDH) genes <em>IDH1</em> and <em>IDH2</em> [<a href="#rid80">80,91</a>], for which specific inhibitors are available (eg, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>), and the <em>BRAF </em>V600E mutation. (See <a class="local">'Ivosidenib for IDH-mutated cholangiocarcinoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a database series of 454 biliary tract cancers, potentially actionable molecular alterations were identified in 30.5 percent, including 39 percent of intrahepatic cholangiocarcinomas, 30 percent of extrahepatic cholangiocarcinomas, and 15 percent of gallbladder cancers [<a href="#rid87">87</a>]. This series used a narrower definition of potentially actionable alterations, and only included those findings for which a tumor-agnostic drug approval existed in the United States in 2022.</p><p></p><p class="headingAnchor" id="H1847140611"><span class="h4">Immunotherapy</span><span class="headingEndMark"> — </span>Immunotherapy with an immune checkpoint inhibitor may be particularly beneficial for patients whose tumors have DNA dMMR/high levels of MSI (MSI-H), programmed cell death 1 ligand 1 (PD-L1) overexpression, or high levels of tumor mutational burden (TMB-high); however, emerging data suggest that durable responses are also possible in patients with intrahepatic cholangiocarcinomas unselected for biomarker status. We would not typically offer second-line immunotherapy to individuals who received <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> or <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> as part of initial therapy.</p><p class="headingAnchor" id="H2677836996"><span class="h5">Biomarker-selected patients</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>dMMR/MSI-H</strong> – It has been hypothesized that tumors that lack the mismatch repair mechanism (ie, mismatch repair deficiency [dMMR]) harbor many more mutations (ie, they are hypermutated) than do tumors of the same type without such mismatch repair defects, and that the neoantigens generated from mutations such as these are more immunogenic than those generated by other mutations. The biologic footprint of dMMR tumors is high levels of MSI (MSI-H).</p><p></p><p class="bulletIndent1">Several steps are required for the immune system to effectively attack tumor cells. Several immune checkpoints exist to dampen the immune response in order to protect against detrimental inflammation and autoimmunity. In the setting of malignancy, such immune checkpoints can result in immune tolerance of the tumor and subsequent progression of the malignancy. Inhibition of these checkpoints might be expected to halt/reverse disease progression. One well-characterized checkpoint being targeted in several tumor types is programmed cell death 1 (PD-1). PD-1 is upregulated on activated T cells, and upon recognition of tumor via the T cell receptor, PD-1 engagement by PD-L1 expressed by tumor or other immune cells infiltrating the tumor tissue can lead to T cell inactivation and a "brake" on immune-mediated tumor eradication. (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p></p><p class="bulletIndent1">Proof of principle that cancers with dMMR might be particularly susceptible to inhibition of the PD-L1/PD-1 interaction was initially provided by a study of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> in dMMR colorectal cancer. Subsequently, it was established that immune checkpoint inhibitor immunotherapy appears to benefit a subset of patients with dMMR tumors regardless of anatomic site of origin or tissue histology. As a result, in May 2017, the FDA approved pembrolizumab for treatment of a variety of advanced solid tumors, including cholangiocarcinomas, that had MSI-H or dMMR, that had progressed following prior treatment, and for which there were no satisfactory alternative treatment options, the first such approval of a tissue-agnostic anticancer treatment. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Other tumors with MSI-H/dMMR'</a>.)</p><p></p><p class="bulletIndent1">Efficacy in dMMR advanced cholangiocarcinoma was shown in the phase II KEYNOTE-158 study, which enrolled 22 patients with cholangiocarcinoma [<a href="#rid92">92</a>]. There were nine objective responses (41 percent), two of which were complete, and the median duration of response ranged from 4.1 to 24.9+ months.</p><p></p><p class="bulletIndent1">The fraction of cholangiocarcinomas that have dMMR has been addressed in the following reports:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study, approximately 3 percent of cholangiocarcinomas had dMMR or MSI-H [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The frequency of dMMR or MSI-H in other studies has been approximately 5 percent each for gallbladder cancer and extrahepatic cholangiocarcinoma and 10 percent each for intrahepatic cholangiocarcinoma and ampullary carcinoma [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower levels of dMMR (1 to 1.3 percent) have been reported for biliary tract cancers when the analysis was limited to individuals with advanced/metastatic disease [<a href="#rid93">93,95</a>].</p><p></p><p class="bulletIndent1">The approach to testing for dMMR is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Assessing mismatch repair'</a> and  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Approach to testing dMMR as a predictive marker'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PD-L1 overexpression</strong> – Other biomarkers such as overexpression of PD-L1 may also predict response to immune checkpoint inhibitor therapy. As an example, in one phase II trial of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> in 46 patients with advanced refractory biliary tract, 18 of 42 tested tumors (43 percent) had PD-L1 overexpression. Overall, 10 patients achieved an investigator-assessed immune partial response  (<a class="graphic graphic_table graphicRef115573" href="/z/d/graphic/115573.html" rel="external">table 10</a>), all of whom had tumors with proficient mismatch repair (pMMR) [<a href="#rid96">96</a>]; 9 of the 10 overexpressed PD-L1. Four responders achieved durable objective response lasting at least one year.</p><p></p><p class="bulletIndent1">On the other hand, a combined analysis of data from the KEYNOTE-028 and 158 studies suggest that <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy has limited activity in advanced biliary tract cancer, irrespective of PD-L1 overexpression [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1">Taken together, these limited data suggest that responses appear to be more frequent in patients with PD-L1 positive tumors, although they have also been documented with PD-L1 negative tumors.</p><p></p><p class="bulletIndent1">Combined immunotherapy approaches may be more beneficial, at least for patients with intrahepatic cholangiocarcinoma, although the predictive value of PD-L1 overexpression remains uncertain. (See <a class="local">'Biomarker-unselected patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor mutational burden</strong> – Biliary tract cancers are generally characterized by low TMB, with only 2.9 to 4.0 percent of cases having high levels of TMB (which has been defined variably) [<a href="#rid98">98-101</a>]. Higher levels of TMB appear to correlate with benefit from immune checkpoint inhibitor immunotherapy in a variety of tumor types [<a href="#rid101">101,102</a>]. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'</a>.)</p><p></p><p class="bulletIndent1">There is scant information on responsiveness of TMB-high cholangiocarcinomas to immune checkpoint inhibitor therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A single published case report documents durable disease control with treatments targeting the PD-1 pathway in a single patient with TMB-high advanced biliary tract cancer [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The KEYNOTE-158 trial, which assessed the benefit of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy in a variety of malignancies, including cholangiocarcinoma, reported a correlation between high TMB and objective response to pembrolizumab monotherapy, and responses were seen in anal, cervical, endometrial, salivary, thyroid, or vulvar carcinoma; mesothelioma; a neuroendocrine tumor; and small cell lung cancer [<a href="#rid104">104</a>]. However, none of the cholangiocarcinomas enrolled in the study had TMB-high disease; 2 of 63 patients without high TMB had an objective response.</p><p></p><p class="bulletIndent2">However, largely based on this study, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is now approved for patients with any solid tumor, including cholangiocarcinoma, that has a TMB ≥10 mut/Mb (as defined by the FDA-approved companion diagnostic test), after progression on standard regimens. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'</a>.)</p><p></p><p class="bulletIndent1">Although it remains uncertain whether this is the appropriate threshold to define high TMB in biliary tract cancer, as validation studies were conducted mainly in lung and urothelial cancers and thresholds for TMB are likely to vary across tumor types, we suggest using the NGS platform FoundationOne CDx assay to assess TMB, as this was the platform used in the KEYNOTE-158 trial, and the use of a threshold TMB of ≥10 mut/Mb to select patients for immune checkpoint inhibitor immunotherapy. Cutoffs for TMB using other platforms have not been identified or linked to the FoundationOne data. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Approach to testing for high levels of TMB'</a>.)</p><p></p><p class="headingAnchor" id="H885682092"><span class="h5">Biomarker-unselected patients</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined immunotherapy for patients with intrahepatic cholangiocarcinoma</strong> – Until further information is available regarding the relevance of additional biomarkers on response rates to combined immunotherapy, a trial of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> is reasonable in the setting of second-line therapy for patients with intrahepatic cholangiocarcinoma who do not have dMMR, high levels of TMB, or PD-L1 overexpression, and who did not receive frontline <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>.</p><p></p><p class="bulletIndent1">Emerging data suggest that durable responses to immune checkpoint inhibitor immunotherapy are possible even in patients unselected for biomarker status. The multicenter open-label phase II CA209-538 clinical trial of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> (3 mg/kg) and <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> (1 mg/kg) every three weeks for four doses followed by nivolumab 3 mg/kg every two weeks for advanced rare cancers included 39 patients with biliary tract cancers, of whom 26 had cholangiocarcinomas, 16 intrahepatic, 10 extrahepatic, and 13 had gallbladder cancer [<a href="#rid105">105</a>]. Among those with cholangiocarcinoma, there were five objective responses, all in the subgroup with intrahepatic tumors, with all responding patients being treated in the second-line setting, and none had microsatellite-unstable tumors. PD-L1 overexpression status was not addressed. Two other patients with intrahepatic cholangiocarcinoma had stable disease for a disease control rate of 44 percent in this group. Duration of response ranged from 3 to 14.8 months. None of the ten patients with extrahepatic cholangiocarcinoma had an objective response, but one patient had stable disease as the best response. In the entire group of 39 patients, approximately one-half experienced an immune-related adverse event of any grade, and ≥grade 3 toxic effects occurred in six (15 percent).</p><p></p><p>Until further information is available regarding the relevance of additional biomarkers on response rates to combined immunotherapy, based upon this study, a trial of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> is reasonable in the setting of second-line therapy for patients with intrahepatic cholangiocarcinoma who do not have dMMR, high levels of TMB, or PD-L1 overexpression, and who did not receive frontline <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>. (See <a class="local">'Gemcitabine plus cisplatin and durvalumab'</a> above.)</p><p class="headingAnchor" id="H775211505"><span class="h4">FGFR inhibitors for FGFR fusion-positive tumors</span><span class="headingEndMark"> — </span>Fibroblast growth factor receptor 2 (<em>FGFR2</em>) gene alterations are involved in the pathogenesis of cholangiocarcinoma, and approximately 9 to 16 percent of patients with cholangiocarcinoma (15 to 20 percent of intrahepatic tumors) harbor <em>FGFR2</em> alterations [<a href="#rid90">90,106-109</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemigatinib</strong> – <a class="drug drug_general" data-topicid="127947" href="/z/d/drug information/127947.html" rel="external">Pemigatinib</a> is a selective, oral inhibitor of FGFR 1, 2, and 3. Activity of this drug in previously treated advanced cholangiocarcinoma was addressed in the open-label single arm FIGHT-202 trial; there were three cohorts: patients with FGFR2 fusions or rearrangements (n = 107), patients with other <em>FGF/FGFR</em> alterations (n = 20), or patients with no <em>FGF/FGFR</em> alterations (n = 18) [<a href="#rid90">90</a>]. All patients initiated therapy at 13.5 mg once daily for 14 days, followed by seven days off. The primary end point was objective response rate. At a median follow-up of 17.8 months, 38 (36 percent) patients with FGFR2 fusions or rearrangements had an objective response including three complete responses. Disease control (objective response or stable disease) was achieved by 88 (80 percent). The median duration of response was 7.5 months (95% CI 5.7-14.5). No patients with other <em>FGF/FGFR </em>alterations or who lacked <em>FGF/FGFR </em>alterations achieved a response, although stable disease was seen in eight of the 20 patients with other <em>FGF/FGFR</em> alterations, and in four (22 percent) of those with no identifiable <em>FGF/FGFR</em> alterations.</p><p></p><p class="bulletIndent1">In the entire cohort, treatment was well tolerated overall, with the most frequent adverse event being hyperphosphatemia (60 percent, 12 percent grade 3 or worse  (<a class="graphic graphic_table graphicRef91252" href="/z/d/graphic/91252.html" rel="external">table 11</a>)). Hyperphosphatemia occurred early after treatment initiation (median time to onset 15 days [95% CI 8-47]) and was managed with a low-phosphate diet, concomitant phosphate binders, diuretics, dose reduction, and/or dose interruption. Other grade 3 or worse toxicities included arthralgias, stomatitis, hyponatremia, hypophosphatemia, abdominal pain, and fatigue, all in fewer than 7 percent of patients. Serous retinal detachment due to subretinal fluid accumulation occurred in 6 (4 percent) of 146 patients; all events were grade 1 or 2, except for one grade 3 event. Dry eye occurred in 21 percent overall but was severe in only 1 percent. (See  <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">"Ocular side effects of systemically administered chemotherapy", section on 'Fibroblast growth factor receptor (FGFR) inhibitors'</a>.)</p><p></p><p class="bulletIndent1">Largely based on these data, <a class="drug drug_general" data-topicid="127947" href="/z/d/drug information/127947.html" rel="external">pemigatinib</a> has been approved by the US FDA for adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a <em>FGFR2</em> fusion or other rearrangement as detected by an FDA-approved test [<a href="#rid110">110</a>]. The approved dose is 13.5 mg once daily for 14 consecutive days followed by seven days off [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1">On the basis of these encouraging results, an international, phase III, randomized, active-controlled trial is currently recruiting patients to compare <a class="drug drug_general" data-topicid="127947" href="/z/d/drug information/127947.html" rel="external">pemigatinib</a> with <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> chemotherapy as initial therapy for unresectable or metastatic cholangiocarcinoma with <em>FGFR2 </em>rearrangements (FIGHT-302; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3D03656536%26type%3D%26rslt%3D%26age_v%3D%26gndr%3D%26intr%3D%26titles%3D%26outc%3D%26spons%3D%26lead%3D%26id%3D%26cntry%3D%26state%3D%26city%3D%26dist%3D%26locn%3D%26rsub%3D%26strd_s%3D%26strd_e%3D%26prcd_s%3D%26prcd_e%3D%26sfpd_s%3D%26sfpd_e%3D%26rfpd_s%3D%26rfpd_e%3D%26lupd_s%3D%26lupd_e%3D%26sort%3D&amp;token=pdJOmvHdfatZaDOf3MSkg2CEFfYVVOy%2FJ%2B%2FbecC26NJHdKwJdosT6hlf6DR5NPHvN8TLjH6cx%2FHQ3WQHFLV%2BA%2Buhy%2Bi0pxMc%2FoiPaarBD%2BHDAKQB%2FH0FwzBFL3mP6AyiZdvIsDMzMhB9yEkBOBKlPu%2BQqoteV7irqTuFyMw99gr4J6h%2B0zv9EJeyLy10opd8hht1Ur6%2BqWV%2BmNQyuaooy5ptcjvc1HKmxmG%2FK5gdzFY%3D&amp;TOPIC_ID=2524" target="_blank">NCT03656536</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infigratinib</strong> – <a class="drug drug_general" data-topicid="131754" href="/z/d/drug information/131754.html" rel="external">Infigratinib</a> is another FGFR1-3 selective oral tyrosine kinase inhibitor. Activity in patients with advanced cholangiocarcinoma, progression on one or more lines of systemic therapy, and <em>FGFR2</em> gene fusions or rearrangements was shown in a preliminary report of a phase II trial, presented at the 2021 ASCO Gastrointestinal Cancers Symposium [<a href="#rid112">112</a>]. Of the 108 patients enrolled, 83 (77 percent) had <em>FGFR2</em> gene fusions and the remainder had rearrangements; all patients received the drug at 125 mg orally daily for 21 days of each 28-day cycle. At a median follow-up of 10.6 months, there were 25 objective responses (23 percent), one complete, and the median duration of response was five months (range 0.9 to 19.1 months). Responses were more likely in patients treated in the second-line versus the third- or later-line setting (34 versus 13 percent). The most common treatment-emergent adverse effects were hyperphosphatemia (76 percent), eye disorders (68 percent, including one grade 3 central serous retinopathy), stomatitis (55 percent), and fatigue (40 percent). The most common severe adverse events were stomatitis (15 percent), hyponatremia, and hypophosphatemia (13 percent each). (See  <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">"Ocular side effects of systemically administered chemotherapy", section on 'Fibroblast growth factor receptor (FGFR) inhibitors'</a>.)</p><p></p><p class="bulletIndent1">Largely based upon these data, <a class="drug drug_general" data-topicid="131754" href="/z/d/drug information/131754.html" rel="external">infigratinib</a> was granted accelerated approval by the US FDA for adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a <em>FGFR2</em> fusion or other rearrangement as detected by an FDA-approved test [<a href="#rid113">113</a>]. The approved dose of infigratinib is 125 mg orally once daily for 21 consecutive days, followed by 7 days off therapy, in 28-day treatment cycles, until disease progression or unacceptable toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Futibatinib</strong> – <a class="drug drug_general" data-topicid="139775" href="/z/d/drug information/139775.html" rel="external">Futibatinib</a> is a highly selective, irreversible <em>FGFR1</em>–<em>4 </em>inhibitor. The approved dose is 20 mg orally, once daily, until disease progression or unacceptable toxicity.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="139775" href="/z/d/drug information/139775.html" rel="external">Futibatinib</a> was evaluated in an open-label phase II trial (FOENIX-CCA2) of 103 patients with intrahepatic cholangiocarcinoma harboring <em>FGFR2</em> fusion/rearrangements with disease progression after one or more prior treatments [<a href="#rid114">114</a>]. At median follow-up of 17 months, the confirmed objective response rate was 42 percent (43 patients) and the median duration of response was 10 months. Median progression-free survival was nine months, with a one-year progression-free survival rate of 40 percent. Median overall survival was 22 months, with a one-year overall survival rate of 72 percent. The most common treatment-related adverse reactions were hyperphosphatemia (85 percent), alopecia (33 percent), dry mouth (30 percent), diarrhea (28 percent), dry skin (27 percent), and fatigue (25 percent).</p><p></p><p>Based on these data, <a class="drug drug_general" data-topicid="139775" href="/z/d/drug information/139775.html" rel="external">futibatinib</a> was granted an accelerated approval by the US FDA for treatment of locally advanced/metastatic intrahepatic cholangiocarcinoma with an <em>FGFR2</em> gene rearrangement or fusion [<a href="#rid115">115</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erdafitinib</strong> – <a class="drug drug_general" data-topicid="121054" href="/z/d/drug information/121054.html" rel="external">Erdafitinib</a> is an oral selective pan-FGFR tyrosine kinase inhibitor. The use of erdafitinib remains investigational in patients with FGFR-altered biliary tract tumors.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="121054" href="/z/d/drug information/121054.html" rel="external">Erdafitinib</a> was evaluated in a phase II trial (RAGNAR) of 217 patients with metastatic tumor of any histology (except urothelial cancer) with a known <em>FGFR1-4</em> alteration [<a href="#rid116">116</a>]. Among the subgroup of 31 patients with cholangiocarcinoma, objective responses were seen in 16 patients (52 percent). </p><p></p><p class="headingAnchor" id="H3346113276"><span class="h4">Ivosidenib for IDH-mutated cholangiocarcinoma</span><span class="headingEndMark"> — </span>Mutations in the isocitrate dehydrogenase (IDH) genes are present in up to 25 percent (<em>IDH1</em>) and approximately 3 percent (<em>IDH2</em>) of cholangiocarcinomas; mutations are particularly frequent (up to 20 percent) in intrahepatic cases [<a href="#rid80">80,91,117,118</a>], for which specific inhibitors are available (eg, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a>, <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">enasidenib</a>). As an example, in a combined phase I/II study of ivosidenib in 73 patients with advanced <em>IDH1</em>-mutated cholangiocarcinoma, there were four partial responses, and median progression-free survival was 3.8 months [<a href="#rid91">91</a>]. <em>IDH1</em> is mutated in up to 25 percent of cholangiocarcinomas, especially intrahepatic [<a href="#rid91">91</a>]; the frequency of <em>IDH2</em> mutations is lower (3 percent in one study [<a href="#rid117">117</a>]).</p><p></p><p>Benefit for <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a> in patients with <em>IDH1</em>-mutant advanced cholangiocarcinoma was further addressed in the placebo-controlled randomized phase III ClarlDHy trial, which enrolled 187 patients with previously treated, progressive advanced (93 percent metastatic) cholangiocarcinoma. The ivosidenib dose was 500 mg once daily in continuous 28-day cycles. In the latest analysis individuals receiving ivosidenib had modestly but significantly better median progression-free survival and a trend toward better overall survival (10.3 versus 7.5 months, HR 0.79, 95% CI 0.56-1.12) [<a href="#rid119">119</a>]. This result was likely influenced by crossover from the placebo to active treatment group; the crossover-adjusted overall survival in the placebo group (as derived using the rank-preserving structural failure time model) was 5.1 months (HR for death with ivosidenib 0.49, 95% CI 0.34-0.70). Notably, in an earlier analysis, 32 percent of the patients receiving ivosidenib had not progressed at six months, and 22 percent were still progression free at 12 months; no patient in the placebo arm lacked disease progression at the six-month point [<a href="#rid120">120</a>]. Common treatment-related adverse effects included nausea, diarrhea, fatigue, cough, abdominal pain, ascites, anorexia, anemia, and vomiting; most were low grade.</p><p>Largely based upon these data, <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">ivosidenib</a> has been approved by the US FDA for treatment of adults with previously treated, locally advanced, or metastatic cholangiocarcinoma with an <em>IDH1</em> mutation, as detected by an FDA-approved test [<a href="#rid121">121</a>]. While this drug may provide modest benefit for a small subset of patients, it may cost as much as USD $1000 per day, a fact that will likely limit general access.</p><p class="headingAnchor" id="H3771639397"><span class="h4">TRK inhibitor therapy for TRK fusion-positive cancers</span><span class="headingEndMark"> — </span>Another option for treatment at progression for patients who have neurotrophic tyrosine receptor kinase (<em>NTRK</em>) gene rearrangements is <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>. Genomic translocations that lead to the constitutive activation of receptor tyrosine kinases are rare overall in cholangiocarcinoma (3.6 percent for intrahepatic cholangiocarcinoma in one report) [<a href="#rid106">106,122</a>]. However, the potential efficacy of larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor, was shown in a combined analysis of 55 patients with various TRK fusion-positive malignancies enrolled in three trials, two of whom had a primary cholangiocarcinoma [<a href="#rid123">123</a>]. In the entire cohort, the overall response rate by independent review was 75 percent, and responses appeared durable, with 86 percent of responders still on treatment or having undergone surgery that was intended to be curative at a median follow-up of 9.4 months. One of the two cholangiocarcinoma tumors had objective tumor shrinkage. Treatment was well tolerated; no responding patients discontinued larotrectinib due to an adverse event. In a safety analysis of 176 patients enrolled across all three trials, the most common adverse reactions (≥20 percent) included elevations in transaminases, fatigue, nausea, vomiting, dizziness, diarrhea, constipation, and cough [<a href="#rid124">124</a>].</p><p class="bulletIndent1">In November 2018, <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> was approved by the FDA for use in adults and children with solid tumors with an <em>NTRK</em> gene fusion and without a known acquired resistance mutation that are either metastatic or where surgical resection is likely to result in severe morbidity who have no satisfactory alternative treatments or whose cancer has progressed following treatment. A similar drug, <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>, was approved in Japan for treatment of 10 tumor types with an <em>NTRK</em> gene fusion (including cholangiocarcinoma), and this drug was approved by the FDA for cancers with an <em>NTRK</em> gene fusion in August 2019. (See  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Treatment with TRK inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H2726164288"><span class="h4">BRAF V600E-mutated cancers</span><span class="headingEndMark"> — </span>Specific mutations in the <em>BRAF</em> gene (<em>BRAF</em> V600E) are reported in approximately 5 percent of biliary tract cancers, especially intrahepatic cholangiocarcinomas [<a href="#rid125">125,126</a>]. Benefit from the combination of the BRAF inhibitor <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> (which reversibly and selectively inhibits mitogen-activated extracellular kinase [MEK], a downstream effector of BRAF) was shown in the phase II open-label ROAR trial (47 percent objective response rate by independent assessment among 43 evaluable patients; and additional 14 percent had stable disease) [<a href="#rid127">127</a>]. The median progression-free survival was nine months. Most of these patients had received two or more lines of prior therapy. Benefit for combined dabrafenib and trametinib was also shown in the NCI-MATCH Trial Subprotocol H, in which three of four advanced cholangiocarcinomas had a partial response, one of which was ongoing at 29 months [<a href="#rid128">128</a>].</p><p>The combination of <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> and <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> has accelerated approval from the FDA for the treatment of adult and pediatric patients one year of age and older with unresectable or metastatic solid tumors harboring mutations in <em>BRAF</em> V600E following prior treatment and with no satisfactory alternative treatment options [<a href="#rid129">129,130</a>].</p><p class="headingAnchor" id="H3636199900"><span class="h4">RET fusion-positive tumors</span><span class="headingEndMark"> — </span><em>RET</em> fusions are rare in cholangiocarcinoma [<a href="#rid131">131</a>]. However, in September 2022, the US FDA granted a tissue-agnostic, accelerated approval to the RET tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> for adult patients with locally advanced or metastatic solid tumors, including cholangiocarcinomas, with a <em>RET</em> gene fusion and disease progression on or following prior systemic treatment who have no satisfactory alternative treatment options. The phase I/II basket trial (LIBRETTO-001) of selpercatinib for <em>RET</em> fusion positive solid tumors included only one patient with cholangiocarcinoma, but there was a partial response [<a href="#rid132">132</a>].</p><p class="headingAnchor" id="H244929969"><span class="h4">HER2-positive tumors</span><span class="headingEndMark"> — </span>Regimens that target human epidermal growth factor receptor 2 (HER2) are used as later-line therapy for HER2-positive metastatic cholangiocarcinoma. Amplification of the <em>HER2</em> oncogene or overexpression of the HER2 protein is seen among approximately 5 to 20 percent of cholangiocarcinomas [<a href="#rid80">80,100,133-135</a>]. <em>HER2</em> molecular alterations are particularly enriched in extrahepatic cholangiocarcinoma.</p><p class="headingAnchor" id="H101006328"><span class="h5">Selection of therapy</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic HER2-positive cholangiocarcinoma who progress on <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, platinum, and/or fluorouracil-based chemotherapy and have no prior exposure to HER2-targeted agents, we suggest either <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> plus <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a> or trastuzumab plus <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> rather than other systemic agents, as these regimens have good objective response rates with an acceptable toxicity profile. Either of these agents are appropriate as they have not been directly compared in randomized trials. (See <a class="local">'Trastuzumab plus pertuzumab'</a> below and <a class="local">'Trastuzumab plus tucatinib'</a> below.)</p><p><a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> is an alternative option, but patients should be cautioned about the risk of interstitial lung disease. (See <a class="local">'Fam-trastuzumab deruxtecan'</a> below.)</p><p class="headingAnchor" id="H1774206600"><span class="h5">Trastuzumab plus pertuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">Trastuzumab</a> plus <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a> is a preferred option for later-line therapy in HER2-positive metastatic cholangiocarcinoma.</p><p>In an open-label phase II basket study (MyPathway), 39 patients with previously treated, HER2 amplified/overexpressed and <em>RAS</em> wildtype biliary tract cancers were treated with <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> plus <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a>. At median follow-up of eight months, objective responses were seen in 9 patients (23 percent) [<a href="#rid136">136</a>]. Median PFS and OS were 4 and 11 months, respectively. The combination was well-tolerated (grade ≥3 toxicity rate and serious treatment-emergent adverse event rate of 8 and 25 percent, respectively).</p><p class="headingAnchor" id="H196978141"><span class="h5">Trastuzumab plus tucatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">Trastuzumab</a> plus <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a>, an oral tyrosine kinase inhibitor highly selective for HER2, is a preferred option for later-line therapy in HER2-positive metastatic cholangiocarcinoma.</p><p><a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">Trastuzumab</a> plus <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> was evaluated in a phase II basket study (SGNTUC-019) of 30 patients with previously treated HER2 overexpressing or amplified metastatic biliary tract cancer and no prior exposure to HER2 targeted therapy [<a href="#rid137">137</a>]. At median follow-up of 11 months, objective responses were seen in 14 patients (47 percent). Median PFS and OS were 6 and 16 months, respectively. Grade ≥3 toxicity rate was 60 percent, including cholangitis, decreased appetite, and nausea (10 percent each), which were generally not related to therapy.</p><p class="headingAnchor" id="H3912479304"><span class="h5">Fam-trastuzumab deruxtecan</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a>, an HER2-directed antibody drug conjugate, is an option for treatment-refractory HER2-positive cholangiocarcinoma. However, patients should be cautioned about the risk of interstitial lung disease with this agent.</p><p>The efficacy of <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> in treatment-refractory cholangiocarcinoma has been demonstrated in early phase clinical trials [<a href="#rid138">138,139</a>]. In a phase II trial (HERB), fam-trastuzumab deruxtecan was evaluated in a subgroup of 24 patients with HER2-positive biliary tract cancers who progressed on prior gemcitabine-based therapy. In preliminary results, objective responses were seen in 8 of 22 patients (36 percent). Median PFS and OS were 4 and 7 months, respectively [<a href="#rid138">138</a>]. Some clinical efficacy was also seen in the subgroup of eight patients with HER2 low tumors. However, the rate of any grade treatment-related interstitial lung disease in the entire cohort was 25 percent. In another phase II trial (DESTINY-PanTumor02), similar results were seen among the subgroup of patients with biliary tract tumors [<a href="#rid139">139</a>]. </p><p class="headingAnchor" id="H3467455123"><span class="h5">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zanidatamab</strong> – Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, is investigational for the treatment of cholangiocarcinoma. Zanidatamab was evaluated in an open-label phase II trial (HERIZON-BTC-01) of 80 patients with advanced or metastatic HER2-positive biliary tract cancers who progressed on gemcitabine-based therapy and had no prior exposure to HER2-targeted therapy [<a href="#rid140">140</a>]. At median follow-up of 12 months, the objective response rate was 41 percent. Median PFS and OS were 6 and not reached. No responses to zanidatamab were seen among the seven patients with HER2-negative or low tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lapatinib</strong> – Data suggest minimal efficacy with single-agent <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a> in previously treated HER2-positive biliary tumors [<a href="#rid141">141,142</a>].</p><p></p><p class="headingAnchor" id="H1161052287"><span class="h4">KRAS G12C mutant tumors</span><span class="headingEndMark"> — </span>Patients with treatment-refractory metastatic cholangiocarcinoma that harbors a <em>KRAS</em> G12C mutation should be encouraged to enroll in clinical trials, where available.</p><p><em>KRAS </em>G12C mutations occur in approximately one percent of patients with biliary tract tumors [<a href="#rid143">143,144</a>]. Studies are ongoing to evaluate agents that target KRAS G12C, such as <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a>. The use of adagrasib remains investigational in <em>KRAS</em> G12C mutant cholangiocarcinoma.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adagrasib</strong> – <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">Adagrasib</a> was evaluated in an open-label phase II trial (KRYSTAL-1) of 64 patients with <em>KRAS</em> G12C mutated, treatment-refractory solid tumors of various histologies, excluding non-small cell lung cancer and colorectal cancer [<a href="#rid145">145</a>]. Among the subgroup of 12 patients with biliary tract tumors, objective responses were seen in five patients (42 percent). The objective response rate among those with cholangiocarcinomas was 50 percent (four of eight patients). Median PFS and OS for those with biliary tract tumors was 9 and 15 months, respectively.</p><p></p><p class="headingAnchor" id="H1484433135"><span class="h4">What is the role of EGFR inhibitors?</span><span class="headingEndMark"> — </span>There is no established role for EGFR inhibitors in the treatment of metastatic cholangiocarcinoma. The addition of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> to chemotherapy failed to improve overall survival in randomized trials [<a href="#rid146">146,147</a>]. Early phase clinical trials have demonstrated clinical efficacy for <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a> as a single agent or in combination with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, [<a href="#rid71">71,148</a>], but further data are necessary prior to the routine use of this agent in metastatic cholangiocarcinoma.</p><p class="headingAnchor" id="H815535935"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>Patients with advanced biliary tract cancer are a heterogeneous group, comprising both locally advanced and metastatic disease, as well as a variety of primary disease sites (intrahepatic bile ducts, extrahepatic bile ducts, gallbladder, and ampulla). This heterogeneity complicates assessment of treatment efficacy.</p><p>The prognostic influence of these and other factors in patients with advanced biliary tract cancer can be illustrated by a Korean series of 213 patients with advanced biliary tract cancer who were either enrolled in one of two prospective phase II studies or included in a retrospective cohort study of patients receiving initial chemotherapy [<a href="#rid149">149</a>]. In a multivariate analysis, metastatic disease, an intrahepatic primary site, the presence of liver metastases, a poor Eastern Cooperative Oncology Group (ECOG) performance status  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a>), and an elevated level of serum alkaline phosphatase were significant predictors of overall survival. Using these five variables, the authors developed a prognostic index to stratify patients into low, intermediate, and high-risk groups with different median (11.5, 7.3, and 3.6 months, respectively) and one-year survivals (48, 26, and 4 percent, respectively). Although these results are not surprising, they demonstrate the variability of the clinical presentation and outcomes among patients with advanced biliary tract cancer. The broad spectrum of clinical courses and the range of prognostic factors must be kept in mind when assessing the results of investigational studies of new treatments.</p><p>Prognostic nomograms based on other factors have also been developed [<a href="#rid150">150</a>]. An important point is that these are prognostic and not predictive models, and they cannot be used to predict which patients are more versus less likely to respond to systemic chemotherapy.</p><p class="headingAnchor" id="H3532206862"><span class="h1">DRUG SHORTAGES</span><span class="headingEndMark"> — </span>There may be any number of cancer therapies in short supply at various times. Guidance in the setting of drug shortages has been provided by the American Society of Clinical Oncology  (<a class="graphic graphic_table graphicRef141828" href="/z/d/graphic/141828.html" rel="external">table 4</a>). </p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – The approach to systemic therapy for advanced or metastatic cholangiocarcinoma is evolving. We encourage enrollment in clinical trials, where available. For patients who decline or are ineligible for clinical trials, our approach to initial therapy is based on patient performance status and bilirubin levels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Good performance status and no hyperbilirubinemia</strong> – For most patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than two  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a>) and no hyperbilirubinemia (ie, total bilirubin less than 2.5 times the upper limit of normal), we suggest the addition of immunotherapy (either <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> or <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>) to <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef89633" href="/z/d/graphic/89633.html" rel="external">table 2</a>) as initial treatment (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>), as these chemoimmunotherapy regimens improved overall survival and demonstrated durable responses in randomized trials. (See <a class="local">'Good performance status and no hyperbilirubinemia'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Although either chemoimmunotherapy regimen is appropriate, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> has the advantage of a simpler maintenance therapy with single-agent durvalumab. (See <a class="local">'Gemcitabine plus cisplatin and durvalumab'</a> above and <a class="local">'Gemcitabine plus cisplatin and pembrolizumab'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who decline chemoimmunotherapy or are anticipated to not tolerate its toxicities, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>  (<a class="graphic graphic_table graphicRef89633" href="/z/d/graphic/89633.html" rel="external">table 2</a>) is an appropriate alternative. (See <a class="local">'Gemcitabine plus cisplatin'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other options for initial therapy include <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, gemcitabine plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, gemcitabine plus <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">nabpaclitaxel</a>, and gemcitabine plus S-1 (where available). (See <a class="local">'Other regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Good performance status, persistent hyperbilirubinemia</strong> – For patients with a good PS who have hyperbilirubinemia despite stenting, we prefer a non-gemcitabine-based regimen, such as LV-modulated FU  (<a class="graphic graphic_table graphicRef65525" href="/z/d/graphic/65525.html" rel="external">table 6</a>) or a fluoropyrimidine plus <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>. (See <a class="local">'Good performance status and persistent biliary obstruction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Borderline performance status or extensive comorbidity</strong> – Reasonable initial therapy options for patients with a borderline PS or extensive comorbidity include LV-modulated FU  (<a class="graphic graphic_table graphicRef65525" href="/z/d/graphic/65525.html" rel="external">table 6</a>), <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> monotherapy, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> monotherapy, or S-1 alone (where available). (See <a class="local">'Borderline performance status'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Later lines of therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior </strong><strong>gemcitabine</strong><strong> plus </strong><strong>cisplatin</strong> – For most patients who have disease progression while receiving <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and who retain an adequate performance status and lack potentially actionable molecular targets, we suggest treatment with FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">table 8</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other alternatives include <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (CAPOX  (<a class="graphic graphic_table graphicRef89431" href="/z/d/graphic/89431.html" rel="external">table 12</a>)), <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a> plus LV-modulated FU  (<a class="graphic graphic_table graphicRef109026" href="/z/d/graphic/109026.html" rel="external">table 9</a>), a fluoropyrimidine alone, or GEMOX with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>. (See <a class="local">'Gemcitabine plus oxaliplatin'</a> above and <a class="local">'Patients initially treated with gemcitabine plus cisplatin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior </strong><strong>gemcitabine</strong><strong> plus </strong><strong>oxaliplatin</strong> – For patients failing GEMOX, appropriate choices for a second-line regimen include <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, or short-term infusional FU plus LV and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> (FOLFIRI) with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>  (<a class="graphic graphic_table graphicRef64505" href="/z/d/graphic/64505.html" rel="external">table 13</a>). (See <a class="local">'Cytotoxic chemotherapy'</a> above and  <a class="medical medical_review" href="/z/d/html/85683.html" rel="external">"Treatment protocols for hepatobiliary cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Molecularly targeted therapy</strong> – Most patients with advanced cholangiocarcinomas may harbor a molecular alteration for which targeted treatment is available. These include (see <a class="local">'Molecularly targeted therapy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>dMMR, PD-L1 overexpression, or high TMB</strong> – Immunotherapy for patients with deficient DNA mismatch repair (dMMR), overexpression of programmed cell death ligand 1 (PD-L1), or high levels of tumor mutational burden (TMB) who did not receive <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> or <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> as part of initial therapy. (See <a class="local">'Biomarker-selected patients'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Fibroblast growth factor receptor 2 (</strong><strong><em>FGFR2</em></strong><strong>) alteration</strong> – <a class="drug drug_general" data-topicid="127947" href="/z/d/drug information/127947.html" rel="external">Pemigatinib</a>, <a class="drug drug_general" data-topicid="131754" href="/z/d/drug information/131754.html" rel="external">infigratinib</a>, or <a class="drug drug_general" data-topicid="139775" href="/z/d/drug information/139775.html" rel="external">futibatinib</a>. (See <a class="local">'FGFR inhibitors for FGFR fusion-positive tumors'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Isocitrate dehydrogenase (</strong><strong><em>IDH</em></strong><strong>) mutation</strong> – <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">Ivosidenib</a>. (See <a class="local">'Ivosidenib for IDH-mutated cholangiocarcinoma'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>TRK fusion-positive</strong> – A tropomyosin receptor kinase (TRK) inhibitor. (See <a class="local">'TRK inhibitor therapy for TRK fusion-positive cancers'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>RET</em></strong><strong> fusion-positive</strong> – <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">Selpercatinib</a>. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>BRAF</em></strong><strong> V600E</strong> <strong>mutation</strong> – The combination of a BRAF and mitogen-activated extracellular kinase (MEK) inhibitor for those with <em>BRAF</em> V600E mutations. (See <a class="local">'BRAF V600E-mutated cancers'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>HER2-positive disease</strong> – For patients with advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive cholangiocarcinoma who progress on <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, platinum, and/or fluorouracil-based chemotherapy and have no prior exposure to HER2-targeted agents, we suggest either <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> plus <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a> or trastuzumab plus <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> rather than other systemic agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> is an alternative option, but patients should be cautioned about the risk of interstitial lung disease. (See <a class="local">'HER2-positive tumors'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No actionable molecular alteration</strong> – For patients without a molecular alteration, or those with molecular alterations for which a targeted treatment is not available, clinical trial enrollment is encouraged, where available. (See <a class="local">'Next-generation sequencing to identify actionable molecular abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunotherapy</strong> – For patients with intrahepatic cholangiocarcinoma who do not have dMMR, high levels of TMB, or PD-L1 overexpression, and who did not receive initial treatment with <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> or <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, a trial of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> is reasonable for second-line therapy or beyond. (See <a class="local">'Biomarker-unselected patients'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593.</a></li><li><a class="nounderline abstract_t">Lamarca A, Ross P, Wasan HS, et al. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. J Natl Cancer Inst 2020; 112:200.</a></li><li class="breakAll">Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence, published online 6/1/22. DOI: https://evidence.nejm.org/doi/10.1056/EVIDoa2200015 (Accessed on July 13, 2022).</li><li><a class="nounderline abstract_t">Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401:1853.</a></li><li class="breakAll">FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. News release. FDA. September 2, 2022. https://bit.ly/3TOU798 https://bit.ly/3TOU798 (Accessed on September 06, 2022).</li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on January 24, 2024).</li><li><a class="nounderline abstract_t">Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273.</a></li><li><a class="nounderline abstract_t">Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer 2009; 101:621.</a></li><li><a class="nounderline abstract_t">Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16:279.</a></li><li><a class="nounderline abstract_t">Giuliani F, Gebbia V, Maiello E, et al. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol 2006; 17 Suppl 7:vii73.</a></li><li><a class="nounderline abstract_t">Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103:469.</a></li><li><a class="nounderline abstract_t">Meyerhardt JA, Zhu AX, Stuart K, et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008; 53:564.</a></li><li><a class="nounderline abstract_t">Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96:896.</a></li><li><a class="nounderline abstract_t">Bridgewater J, Lopes A, Palmer D, et al. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer 2016; 114:965.</a></li><li><a class="nounderline abstract_t">Kim ST, Kang JH, Lee J, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 2019; 30:788.</a></li><li><a class="nounderline abstract_t">André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339.</a></li><li><a class="nounderline abstract_t">Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95:848.</a></li><li><a class="nounderline abstract_t">Manzione L, Romano R, Germano D. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology 2007; 73:311.</a></li><li><a class="nounderline abstract_t">André T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008; 99:862.</a></li><li><a class="nounderline abstract_t">Wagner AD, Buechner-Steudel P, Moehler M, et al. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer 2009; 101:1846.</a></li><li><a class="nounderline abstract_t">Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11:48.</a></li><li><a class="nounderline abstract_t">Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23:2332.</a></li><li><a class="nounderline abstract_t">Cho JY, Paik YH, Chang YS, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005; 104:2753.</a></li><li><a class="nounderline abstract_t">Riechelmann RP, Townsley CA, Chin SN, et al. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007; 110:1307.</a></li><li><a class="nounderline abstract_t">Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008; 26:3702.</a></li><li><a class="nounderline abstract_t">Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98:309.</a></li><li><a class="nounderline abstract_t">Iqbal S, Rankin C, Lenz HJ, et al. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol 2011; 68:1595.</a></li><li><a class="nounderline abstract_t">Sahai V, Catalano PJ, Zalupski MM, et al. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2018; 4:1707.</a></li><li><a class="nounderline abstract_t">Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 2019; 5:824.</a></li><li><a class="nounderline abstract_t">Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 2019; 30:1950.</a></li><li><a class="nounderline abstract_t">Kang MJ, Lee JL, Kim TW, et al. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncol 2012; 51:860.</a></li><li><a class="nounderline abstract_t">Kornek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004; 15:478.</a></li><li><a class="nounderline abstract_t">Li H, Zhang ZY, Zhou ZQ, et al. Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget 2016; 7:26888.</a></li><li><a class="nounderline abstract_t">Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 2013; 104:1211.</a></li><li><a class="nounderline abstract_t">Phelip JM, Vendrely V, Rostain F, et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Eur J Cancer 2014; 50:2975.</a></li><li><a class="nounderline abstract_t">Santoro A, Gebbia V, Pressiani T, et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Ann Oncol 2015; 26:542.</a></li><li><a class="nounderline abstract_t">Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28:4581.</a></li><li><a class="nounderline abstract_t">Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev 2018; 4:CD011746.</a></li><li><a class="nounderline abstract_t">Kajanti M, Pyrhönen S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994; 17:223.</a></li><li><a class="nounderline abstract_t">Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2:1245.</a></li><li><a class="nounderline abstract_t">Takada T, Kato H, Matsushiro T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51:396.</a></li><li><a class="nounderline abstract_t">Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9:653.</a></li><li><a class="nounderline abstract_t">Sanz-Altamira PM, Ferrante K, Jenkins RL, et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998; 82:2321.</a></li><li><a class="nounderline abstract_t">Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23:425.</a></li><li><a class="nounderline abstract_t">Chen JS, Jan YY, Lin YC, et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs 1998; 9:393.</a></li><li><a class="nounderline abstract_t">Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995; 31A:1594.</a></li><li><a class="nounderline abstract_t">Patt YZ, Jones DV Jr, Hoque A, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14:2311.</a></li><li><a class="nounderline abstract_t">Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12:183.</a></li><li><a class="nounderline abstract_t">Malik IA, Aziz Z. Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003; 26:124.</a></li><li><a class="nounderline abstract_t">Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101:578.</a></li><li><a class="nounderline abstract_t">Petekkaya I, Gezgen G, Roach EC, et al. Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine. J BUON 2012; 17:796.</a></li><li><a class="nounderline abstract_t">Sasaki T, Isayama H, Nakai Y, et al. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 2013; 71:973.</a></li><li><a class="nounderline abstract_t">Novarino AM, Satolli MA, Chiappino I, et al. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer. Am J Clin Oncol 2013; 36:466.</a></li><li><a class="nounderline abstract_t">Park JS, Oh SY, Kim SH, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 2005; 35:68.</a></li><li><a class="nounderline abstract_t">Suzuki E, Furuse J, Ikeda M, et al. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology 2010; 79:39.</a></li><li><a class="nounderline abstract_t">Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19:4089.</a></li><li><a class="nounderline abstract_t">Jacobson SD, Alberts SR, Mahoney MR, et al. Phase II trial of gemcitabine, 5-fluorouracil, and leucovorin in patients with unresectable or metastatic biliary and gallbladder carcinoma (abstract). Proc Am Soc Clin Oncol 2003; 22:275a.</a></li><li><a class="nounderline abstract_t">Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005; 103:111.</a></li><li><a class="nounderline abstract_t">Ahn DH, Reardon J, Ahn CW, et al. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Int J Cancer 2018; 142:1671.</a></li><li><a class="nounderline abstract_t">Fornaro L, Cereda S, Aprile G, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer 2014; 110:2165.</a></li><li><a class="nounderline abstract_t">Brieau B, Dahan L, De Rycke Y, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer 2015; 121:3290.</a></li><li><a class="nounderline abstract_t">Neuzillet C, Casadei Gardini A, Brieau B, et al. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer 2019; 111:94.</a></li><li><a class="nounderline abstract_t">He S, Shen J, Sun X, et al. A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother 2014; 26:243.</a></li><li><a class="nounderline abstract_t">Lamarca A, Palmer DH, Wasan HS, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol 2019; 37S: ASCO #4003.</a></li><li><a class="nounderline abstract_t">Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22:690.</a></li><li><a class="nounderline abstract_t">Yoo C, Kim KP, Jeong JH, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021; 22:1560.</a></li><li><a class="nounderline abstract_t">Zheng Y, Tu X, Zhao P, et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer 2018; 119:291.</a></li><li><a class="nounderline abstract_t">Kim BJ, Yoo C, Kim KP, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer 2017; 116:561.</a></li><li><a class="nounderline abstract_t">Park BK, Paik YH, Park JY, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 2006; 29:138.</a></li><li><a class="nounderline abstract_t">Guion-Dusserre JF, Lorgis V, Vincent J, et al. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21:2096.</a></li><li><a class="nounderline abstract_t">Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010; 28:3491.</a></li><li><a class="nounderline abstract_t">Iyer RV, Pokuri VK, Groman A, et al. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer. Am J Clin Oncol 2018; 41:649.</a></li><li><a class="nounderline abstract_t">Bréchon M, Dior M, Dréanic J, et al. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. Invest New Drugs 2018; 36:156.</a></li><li><a class="nounderline abstract_t">Demols A, Borbath I, Van den Eynde M, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol 2020; 31:1169.</a></li><li><a class="nounderline abstract_t">Kim RD, Sanoff HK, Poklepovic AS, et al. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer 2020; 126:3464.</a></li><li><a class="nounderline abstract_t">Lee S, Shroff RT, Makawita S, et al. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clin Cancer Res 2022; 28:2229.</a></li><li><a class="nounderline abstract_t">Woo SM, Lee WJ, Han SS, et al. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. Chemotherapy 2012; 58:225.</a></li><li><a class="nounderline abstract_t">Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003; 14:1115.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li><a class="nounderline abstract_t">Valle JW, Lamarca A, Goyal L, et al. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov 2017; 7:943.</a></li><li><a class="nounderline abstract_t">Verlingue L, Hollebecque A, Boige V, et al. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground? Eur J Cancer 2017; 81:161.</a></li><li><a class="nounderline abstract_t">Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev 2017; 36:141.</a></li><li><a class="nounderline abstract_t">Mondaca S, Razavi P, Xu C, et al. Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precis Oncol 2019; 3.</a></li><li><a class="nounderline abstract_t">Dumbrava EEI, Balaji K, Raghav K, et al. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 2019; 3.</a></li><li><a class="nounderline abstract_t">Tella SH, Kommalapati A, Borad MJ, Mahipal A. Second-line therapies in advanced biliary tract cancers. Lancet Oncol 2020; 21:e29.</a></li><li><a class="nounderline abstract_t">Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer 2017; 87:122.</a></li><li><a class="nounderline abstract_t">Mody K, Jain P, El-Refai SM, et al. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precis Oncol 2022; 6:e2100510.</a></li><li><a class="nounderline abstract_t">Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 2019; 120:165.</a></li><li><a class="nounderline abstract_t">Bahleda R, Italiano A, Hierro C, et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin Cancer Res 2019; 25:4888.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21:671.</a></li><li><a class="nounderline abstract_t">Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol 2019; 4:711.</a></li><li><a class="nounderline abstract_t">Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38:1.</a></li><li><a class="nounderline abstract_t">Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357:409.</a></li><li><a class="nounderline abstract_t">Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol 2016; 5:62.</a></li><li><a class="nounderline abstract_t">Middha S, Zhang L, Nafa K, et al. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precis Oncol 2017; 2017.</a></li><li><a class="nounderline abstract_t">Kim RD, Chung V, Alese OB, et al. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol 2020; 6:888.</a></li><li><a class="nounderline abstract_t">Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020; 147:2190.</a></li><li><a class="nounderline abstract_t">Mody K, Starr J, Saul M, et al. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol 2019; 10:1099.</a></li><li><a class="nounderline abstract_t">Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer 2016; 122:3838.</a></li><li><a class="nounderline abstract_t">Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol 2019; 10:652.</a></li><li><a class="nounderline abstract_t">Osipov A, Lim SJ, Popovic A, et al. Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. Clin Cancer Res 2020; 26:4842.</a></li><li><a class="nounderline abstract_t">Goodman AM, Kato S, Bazhenova L, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 2017; 16:2598.</a></li><li><a class="nounderline abstract_t">Gbolahan O, Hashemi-Sadraei N, O'Neil B. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. J Natl Compr Canc Netw 2019; 17:644.</a></li><li><a class="nounderline abstract_t">Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21:1353.</a></li><li><a class="nounderline abstract_t">Klein O, Kee D, Nagrial A, et al. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2020; 6:1405.</a></li><li><a class="nounderline abstract_t">Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014; 19:235.</a></li><li><a class="nounderline abstract_t">Farshidfar F, Zheng S, Gingras MC, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 2017; 18:2780.</a></li><li><a class="nounderline abstract_t">Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol 2014; 45:1630.</a></li><li><a class="nounderline abstract_t">Javle M, Lowery M, Shroff RT, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol 2018; 36:276.</a></li><li class="breakAll">FDA Approves First Targeted Treatment for Patients with Cholangiocarcinoma, a Cancer of Bile Ducts. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-treatment-patients-cholangiocarcinoma-cancer-bile-ducts (Accessed on April 21, 2020).</li><li class="breakAll">Pemigatinib tablets, for oral use. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf (Accessed on April 21, 2020).</li><li class="breakAll">Javle MM, Roychowdhury S, Kelley RK, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement (abstract). J Clin Oncol 39,2021 (suppl3; abstr 265). https://meetinglibrary.asco.org/record/194241/abstract (Accessed on June 02, 2021).</li><li class="breakAll">TRUSELTIQ (infigratinib) capsules, for oral use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf (Accessed on June 02, 2021).</li><li><a class="nounderline abstract_t">Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med 2023; 388:228.</a></li><li class="breakAll">FDA grants accelerated approval to futibatinib for cholangiocarcinoma. US Food and Drug Administration. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma (Accessed on October 03, 2022).</li><li><a class="nounderline abstract_t">Pant S, Schuler M, Iyer G, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 2023; 24:925.</a></li><li><a class="nounderline abstract_t">Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17:72.</a></li><li class="breakAll">Makawita S, Borad MJ, Carapeto F, et al. IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study (abstract). J Clin Oncol 39, 2021 (suppl 15; abstr 4009). Abstraact availabl.e at https://meetinglibrary.asco.org/record/196929/abstract (Accessed on June 09, 2021).</li><li><a class="nounderline abstract_t">Zhu AX, Macarulla T, Javle MM, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021; 7:1669.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Macarulla M, Javle M, et al. LBA10_PR - ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol 2019; 30S: ESMO #v851.</a></li><li class="breakAll">US FDA approval letter for ivosidenib in advanced cholangiocarcinoma. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211192Orig1s008ltr.pdf (Accessed on August 30, 2021).</li><li><a class="nounderline abstract_t">Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015; 5:25.</a></li><li><a class="nounderline abstract_t">Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731.</a></li><li class="breakAll">US Food and Drug Administration (FDA) Label for Larotrectinib https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf?et_cid=40674858&amp;et_rid=931330620&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f211710s000lbl.pdf (Accessed on November 27, 2018).</li><li><a class="nounderline abstract_t">Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol 2016; 7:797.</a></li><li><a class="nounderline abstract_t">Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol 2017; 8:293.</a></li><li><a class="nounderline abstract_t">Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020; 21:1234.</a></li><li><a class="nounderline abstract_t">Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol 2020; 38:3895.</a></li><li class="breakAll">Dabrafenib: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s027lbl.pdf (Accessed on September 06, 2023).</li><li class="breakAll">Trametinib: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s029lbl.pdf (Accessed on September 06, 2023).</li><li><a class="nounderline abstract_t">Li AY, McCusker MG, Russo A, et al. RET fusions in solid tumors. Cancer Treat Rev 2019; 81:101911.</a></li><li><a class="nounderline abstract_t">Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022; 23:1261.</a></li><li><a class="nounderline abstract_t">Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 2015; 34:157.</a></li><li><a class="nounderline abstract_t">Harder J, Waiz O, Otto F, et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15:4511.</a></li><li><a class="nounderline abstract_t">Hiraoka N, Nitta H, Ohba A, et al. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Hum Pathol 2020; 105:9.</a></li><li><a class="nounderline abstract_t">Javle M, Borad MJ, Azad NS, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021; 22:1290.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Mizuno N, Sunakawa Y, et al. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. J Clin Oncol 2023; 41:5569.</a></li><li class="breakAll">Ohba A, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial) (abstract). J Clin Oncol 40, 2022 (suppl 16; abstr 4006). Abstract available online at https://meetings.asco.org/2022-asco-annual-meeting/14362?presentation=208021#208021 (Accessed on June 16, 2022).</li><li><a class="nounderline abstract_t">Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol 2024; 42:47.</a></li><li><a class="nounderline abstract_t">Harding JJ, Fan J, Oh DY, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol 2023; 24:772.</a></li><li><a class="nounderline abstract_t">Peck J, Wei L, Zalupski M, et al. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology 2012; 82:175.</a></li><li><a class="nounderline abstract_t">Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64:777.</a></li><li><a class="nounderline abstract_t">Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type. N Engl J Med 2021; 384:185.</a></li><li><a class="nounderline abstract_t">Salem ME, El-Refai SM, Sha W, et al. Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO Precis Oncol 2022; 6:e2100245.</a></li><li><a class="nounderline abstract_t">Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation. J Clin Oncol 2023; 41:4097.</a></li><li><a class="nounderline abstract_t">Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014; 15:819.</a></li><li><a class="nounderline abstract_t">Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer 2016; 122:574.</a></li><li><a class="nounderline abstract_t">Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24:3069.</a></li><li><a class="nounderline abstract_t">Park I, Lee JL, Ryu MH, et al. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 2009; 115:4148.</a></li><li><a class="nounderline abstract_t">Salati M, Caputo F, Cunningham D, et al. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. Eur J Cancer 2019; 117:84.</a></li></ol></div><div id="topicVersionRevision">Topic 2524 Version 86.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879373" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077311" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077311" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37075781" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37075781" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37075781" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375404" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19672264" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668284" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760299" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628385" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597402" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325704" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27115567" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Quality of life, long-term survivors and long-term outcome from the ABC-02 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30785198" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319238" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16969352" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18493158" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19238628" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19904267" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19932054" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800324" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16294346" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17628484" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18669455" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182984" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556747" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30178032" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30998813" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566666" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22559158" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998852" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27058753" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23763511" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25241229" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25538178" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855823" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29624208" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8192106" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6092556" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8052479" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9681080" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9635523" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955877" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660535" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7488407" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8708722" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300321" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12714880" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15274071" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23335544" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23355041" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22781390" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15709089" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21063134" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600613" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phase II trial of gemcitabine, 5-fluorouracil, and leucovorin in patients with unresectable or metastatic biliary and gallbladder carcinoma (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558814" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114851" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24714745" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26052689" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30826661" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24070164" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33798493" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34656226" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955136" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28081540" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601431" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25717243" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530271" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27849649" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28762171" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32464280" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32453456" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35312753" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22831988" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853355" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28818953" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : New Horizons for Precision Medicine in Biliary Tract Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28628842" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27981460" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32923849" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32923865" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31908303" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Second-line therapies in advanced biliary tract cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29145038" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35675577" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30420614" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31088831" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203698" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31300360" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682550" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28596308" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27829276" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30211344" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32352498" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32359091" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31949927" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27622582" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Biliary cancer: Utility of next-generation sequencing for clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31392046" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32586938" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28835386" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31200359" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32919526" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32729929" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24563076" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28297679" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24837095" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182496" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182496" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182496" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182496" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182496" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652354" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652354" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37541273" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180306" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180306" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34554208" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : LBA10_PR - ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : LBA10_PR - ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527197" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : TRKing down an old oncogene in a new era of targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466156" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466156" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27747093" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Molecular profiling of biliary tract cancer: a target rich disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480068" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818466" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758030" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758030" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758030" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31715421" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : RET fusions in solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712293" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : HER2 expression status in diverse cancers: review of results from 37,992 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19777609" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : EGFR and HER2 expression in advanced biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32891647" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34339623" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37751561" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37751561" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870536" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37276871" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22433475" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19169683" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33497555" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35319967" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37099736" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24852116" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26540314" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809731" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Phase II study of erlotinib in patients with advanced biliary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19536892" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31276980" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
